Clinical outcomes of thyroid tumours with concurrent epithelial and mesenchymal components in 14 dogs (2006–2020)

Abstract

Background While rare, multiple individual case reports have described mixed thyroid tumours in dogs containing both epithelial and mesenchymal neoplastic components. Objectives In this retrospective case series, we describe the clinical presentation, treatment and outcome of 14 dogs of canine thyroid tumours with concurrent mesenchymal and epithelial neoplastic populations. Methods Fourteen cases were retrospectively abstracted from nine institutions. Histopathologic samples and reports were collected from 10/14 dogs and reviewed by a single board‐certified anatomic pathologist. Results All 14 dogs had curative‐intent surgery to remove the thyroid neoplasm. The most common surgery performed was a unilateral thyroidectomy (10/14 dogs). Postoperatively, systemic therapy was administered in eight dogs. Six dogs developed local recurrence with a median time to loco‐regional recurrence of 53 days. Ten dogs developed metastatic disease with the most common metastatic site being the lungs (6/10 dogs), with a median time to metastasis of 93 days. Ten dogs were euthanised due to locoregional or distant progression of their mixed thyroid neoplasm. The overall median survival time was 156 days (95%CI: 49–244). The median survival time for dogs treated with adjuvant therapy was 189 days (95%CI: 24–244), whereas dogs without adjuvant therapy had a median survival time of 156 days (95%CI: 35‐upper limit could not be calculated; p = 0.62). Conclusion The thyroid tumours with both mesenchymal and epithelial components in this small sample set were associated with a poor prognosis after surgical excision with or without adjunctive therapy.

Canine follicular cell and medullary thyroid carcinomas: Immunohistochemical characterization

“…25 Vimentin expression had also been previously reported in canine thyroid carcinomas and in one case report of canine MTC. 11,20,34,36 Surprisingly, immunolabeling for TSHR, NIS, pendrin, and TPO was also observed in canine MTCs. The cause for the expression of proteins of iodine transport and thyroid hormone production in canine MTC is uncertain but may offer an explanation for the scarce reports of iodine uptake by these tumors.…”

“…25 Vimentin expression had also been previously reported in canine thyroid carcinomas and in one case report of canine MTC. 11,20,34,36…”